, Volume 79, Issue 18, pp 1997–2000 | Cite as

Brolucizumab: First Approval

  • Anthony MarkhamEmail author
AdisInsight Report


Brolucizumab (Beovu®) is a low molecular weight, single-chain antibody fragment vascular endothelial growth factor (VEGF) inhibitor being developed by Novartis for the treatment of exudative (wet) age-related macular degeneration (AMD), diabetic macular oedema and macular oedema secondary to retinal vein occlusion. Based primarily on the results of the phase III HAWK and HARRIER trials brolucizumab was recently approved in the US for the treatment of wet AMD. This article summarizes the milestones in the development of brolucizumab leading to this first approval.


Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflicts of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. A. Markham, a contracted employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.


  1. 1.
    Novartis. BEOVU® (brolucizumab-dbll) injection, for intravitreal injection: US prescribing information. 2019., Accessed 11 Nov 2019.
  2. 2.
    Novartis. Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept [media release]. 8 Oct 2019.
  3. 3.
    Alcon. Alcon to acquire Swiss biotechnology firm, ESBATech AG [media release]. 14 Sep 2009.
  4. 4.
    Alcon. Alcon and Novartis complete merger and form new Alcon Division to accelerate global leadership in eye care [media release]. 8 Apr 2011.
  5. 5.
    Novartis. Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off [media release]. 9 Apr 2019.
  6. 6.
    Gaudreault J, Gunde T, Floyd HS, et al. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53(14):3025.Google Scholar
  7. 7.
    Tietz J, Spohn G, Schmid G, et al. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor a for the treatment of retinal disorders [abstract]. Invest Ophthalmol Vis Sci. 2015;56(7):1501.Google Scholar
  8. 8.
    Holz FG, Dugel PU, Weissgerber G, et al. Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study. Ophthalmology. 2016;123(5):1080–9.CrossRefGoogle Scholar
  9. 9.
    Nimz EL, Van TLCW, Yanez JA, et al. Intraocular and systemic pharmacokinetics of brolucizumab (RTH258) in nonhuman primates [abstract]. Invest Ophthalmol Vis Sci. 2016;57(12):4996.Google Scholar
  10. 10.
    Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2019. Scholar
  11. 11.
    Singh RP, Wykoff CC, Tadayoni R, et al. Visual and expanded anatomical outcomes for brolucizumab versus aflibercept in patients with neovascular AMD: 96-week data from HAWK and HARRIER [abstract]. Investig Ophthalm Vis Sci. 2019;60(9):5194.Google Scholar
  12. 12.
    Dugel PU, Lang GE, Razavi S, et al. Predictability of the 12-week dosing status at week 48 for patients receiving brolucizumab in HAWK and HARRIER [abstract]. Investig Ophthalm Vis Sci Conf. 2018;59(9):1455.Google Scholar
  13. 13.
    Dugel PU, Jaffe GJ, Sallstig P, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124(9):1296–304.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations